clinical trial · NCT06679946
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Transthyretin Amyloidosis (ATTR) With CardiomyopathyVutrisiran
brief summary
The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who continued on extended use of vutrisiran, or switched from patisiran.
started
Dec 3, 2024
primary completion
Mar 31, 2028
completion
Mar 31, 2028
last updated
Feb 20, 2026
official title
An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol